Job Trends
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
It was a very busy week for clinical trial announcements, although there were only three that were COVID-19-related. Here’s a look.
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.
The 146,000 square foot facility will benefit Umoja Biopharma to eliminate crucial CAR-T production barriers. There’s a lot more going on, know everything here.
Laronde has managed to secure as much as $440 million from a Series B financing round to support as many as 100 Endless RNA (eRNA) products and drug programs over the next decade.
An alleged plan by Johnson & Johnson to spin off a company solely responsible for its talc-based products in order to mitigate lawsuit damages is still on the table following a ruling by a federal judge.
Gilead won the most recent battle when a U.S. appeals court threw out a $1.2 billion ruling against the company.
It was a busy week for clinical trial news. Here’s a look.
Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.
Pfizer Chief Executive Officer Albert Bourla tapped Aamir Malik to serve as the company’s chief business innovation officer.